Clinical trials: Cutaneous Melanoma
Advanced Malignancies, Ovarian Cancer
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy.
- Conditions
- Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
- Trial name
- NCT04752826
- Testing
- BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly
- Where
- 25 sites in United States, Denmark and 5 more
- Volunteers
- 250 people
- Sponsor
- BioInvent International AB
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer, Melanoma, Malignant
Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial
This trial aims to assess the immunological and metabolic changes induced by the Fasting Mimicking Diet (FMD) in the pre-operative and post-operative setting in breast cancer and melanoma patients.
- Trial name
- DIgesT (NCT03454282)
- Testing
- FMD
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Melanoma (Skin Cancer)
MELanoma Brain Metastasis Treated With CYberknife
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.
- Trial name
- MELCY (NCT07691255)
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Malignant Melanoma
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document…
- Trial name
- NCT00145158
- Testing
- 8 HLA-A2-restricted peptides and Montanide ISA51, 8 HLA-A2-restricted peptides and CpG 7909
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic…
- Trial name
- NCT00107718
- Testing
- SB-485232
- Where
- 20 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Immunotherapy
Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy
PROMIT is a single arm phase 2 trial evaluating the clinical activity of immune checkpoint blockade (ICB) after administration of dacarbazine (DTIC) in patients with unresectable or metastatic, BRAF wildtype melanoma with primary…
- Trial name
- PROMIT (NCT04225390)
- Testing
- Dacarbazine (DTIC)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Diagnoses Disease
Whack-a-Mole: Testing an Intervention to Increase Melanoma Identification
The purpose of this study is to evaluate an interactive game designed to increase people's ability to identify cancerous moles.
- Trial name
- NCT04069104
- Testing
- ABCD Information, UDS information, Standard (clinical) feedback
- Where
- United States
- Volunteers
- 1,849 people, healthy volunteers welcome
- Sponsor
- University of Miami
Melanoma, Cutaneous Malignant
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the…
- Trial name
- SUPRAME (NCT06743126)
- Testing
- IMA203, nivolumab plus relatlimab, lifileucel
- Where
- 71 sites in United States, Canada and 4 more
- Volunteers
- 360 people
- Sponsor
- Immatics US, Inc.
Melanoma (Skin), Lentigo Maligna
Reflectance Confocal Microscopy to Diagnose MM & LM
A reflectance confocal microscope is a machine which is able to examine the upper layers of the skin painlessly and without the need for taking a biopsy.
- Trial name
- NCT03508297
- Testing
- In-vivo imaging
- Where
- United Kingdom
- Volunteers
- 597 people
- Sponsor
- Skin Care Network Ltd.
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Solid Tumors, Hepatocellular Carcinoma (HCC)
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5).
- Conditions
- Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric Cancer
- Trial name
- NCT06636435
- Testing
- CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3
- Where
- 5 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Chiome Bioscience Inc.
Metastatic Melanoma, Malignant Metastatic Melanoma
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
- Conditions
- Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma
- Trial name
- NCT01212276
- Testing
- MORAb-028
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Morphotek
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Non Small Cell Lung Cancer
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
- Trial name
- NCT05366478
- Testing
- Autologous tumor infiltrating lymphocytes (TILs)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Melanoma, Gastrointestinal Cancer
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Background: Exomes are the parts of deoxyribonucleic acid (DNA) that make proteins. Researchers are finding a way to read the letters in the exome. Incorrect letters are called mutations. Tumors contain specific mutations.
- Conditions
- Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT03300843
- Testing
- Peptide loaded dendritic cell vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma Metastatic
Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
The association between microbiota and response to ICI-based therapy reflects the ability of bacterial metabolites to upregulate MHC class I APM component expression and/or function in cancer cells, leading to their elimination…
- Trial name
- NCT07050940
- Testing
- Postbiotic, AntiPD1
- Where
- 5 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Azienda Ospedaliera di Perugia
Lymphoma, Advanced Solid Tumors
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
- Trial name
- NCT04144140
- Testing
- E7766
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Metastatic Melanoma
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma
This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and…
- Trial name
- NCT00881049
- Testing
- Imatinib (Gleevec)
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Peking University
Solid Tumor, Adult, Non-small Cell Lung Cancer
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Trial name
- NCT04913285
- Testing
- KIN-2787, KIN-2787 and binimetinib
- Where
- 48 sites in United States, Australia and 5 more
- Volunteers
- 400 people
- Sponsor
- Pierre Fabre Medicament
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.